Journey Medical CFO Receives $450K+ Stock Grant Package in Retention Move

Journey Medical Corp CFO Joseph Benesch reported significant equity compensation grants on June 17, 2025.

Rhea-AI Filing Summary

Journey Medical Corp CFO Joseph Benesch reported significant equity compensation grants on June 17, 2025. The insider received two major awards:

• 28,907 Restricted Stock Units (RSUs) vesting in three equal annual installments from January 2026 to January 2028
• 41,860 Stock Options with a strike price of $6.31, vesting similarly over three years and expiring June 17, 2035

Following these transactions, Benesch now beneficially owns 232,464 shares directly, including various restricted stock units. These equity grants appear to be part of the company's executive compensation program under their 2015 Stock Plan. The awards' three-year vesting schedule suggests a long-term retention strategy for the CFO position.

Insider Trade Summary

Grant/Award: 70,767 shares

Grant/Award 2 txns

Insider Benesch Joseph

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	41,860	$0.00	$0.00
Grant/Award	Common Stock, $0.0001 par value	28,907	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 41,860 contracts (Direct); Common Stock, $0.0001 par value — 232,464 shares (Direct)

Footnotes (3)

1. F1. On June 17, 2025, the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 9,636 shares on January 1, 2026, 9,636 shares on January 1, 2027 and 9,635 shares on January 1, 2028.
2. F2. Includes restricted stock units, which vest over various time periods.
3. F3. On June 17, 2025, the reporting person was granted 41,860 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 13,953 shares on January 1, 2026, 13,953 shares on January 1, 2027 and 13,954 shares on January 1, 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many restricted stock units (RSUs) did DERM's CFO Joseph Benesch receive on June 17, 2025?

DERM's CFO Joseph Benesch received 28,907 restricted stock units on June 17, 2025. These RSUs will vest in three tranches: 9,636 shares on January 1, 2026, 9,636 shares on January 1, 2027, and 9,635 shares on January 1, 2028.

What is the exercise price of the stock options granted to DERM's CFO in June 2025?

The stock options were granted with an exercise price of $6.31 per share. These options were issued on June 17, 2025, and will expire on June 17, 2035.

How many total shares does DERM's CFO Joseph Benesch own after the June 2025 transactions?

Following the reported transactions, Joseph Benesch beneficially owns 232,464 shares directly (including restricted stock units that vest over various time periods), plus 41,860 stock options granted in the latest transaction.

What is the vesting schedule for the stock options granted to DERM's CFO in June 2025?

The 41,860 stock options granted on June 17, 2025, will vest in three approximately equal tranches: 13,953 shares on January 1, 2026, 13,953 shares on January 1, 2027, and 13,954 shares on January 1, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/20/2025 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Benesch Joseph

(Last) (First) (Middle)

C/O JOURNEY MEDICAL CORPORATION

9237 E VIA DE VENTURA BLVD., SUITE 105

(Street)

SCOTTSDALE AZ 85258

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Journey Medical Corp [ DERM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 par value	06/17/2025		A		28,907(1)	A	$0	232,464(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.31	06/17/2025		A		41,860		(3)	06/17/2035	Common Stock, $0.0001 par value	41,860	$0	41,860	D

Explanation of Responses:

1. On June 17, 2025, the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 9,636 shares on January 1, 2026, 9,636 shares on January 1, 2027 and 9,635 shares on January 1, 2028.

2. Includes restricted stock units, which vest over various time periods.

3. On June 17, 2025, the reporting person was granted 41,860 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 13,953 shares on January 1, 2026, 13,953 shares on January 1, 2027 and 13,954 shares on January 1, 2028.

	/s/ Ramsey Alloush, attorney-in-fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.